These innovative agents represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose levels. Trizepatide, on the other hand, targets all three incretin receptors – GLP-1, GIP, and insulin – leading to a synergistic effect.